CheckMate 649 Archives - Medical Conferences

CheckMate 649: Nivolumab plus chemotherapy continues to deliver efficacy benefit in gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2024

Type

News article

13 February 2024 14:03

3-year follow-up data confirms benefits of nivolumab plus chemotherapy

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer, NY, USA

Trial

Phase 3, CheckMate 649

Conference

ASCO GI 2023

Type

Peer-reviewed article

17 March 2023 08:10

Nivolumab in gastric cancer: Efficacy update and the role of gut microbiome

Presented By

Dr Kohei Shitara, National Cancer Center Hospital East, Japan; Dr Yu Sunakawa, St. Marianna University School of Medicine, Japan

Trial

Phase 3, CheckMate 649, DELIVER

Conference

ASCO GI 2022

Type

Peer-reviewed article

21 March 2022 11:11

Consistent benefit of anti-PD-1 therapy for oesophageal and gastric cancer

Presented By

Dr Yelena Janjigian, Memorial Sloan Kettering Cancer Center, NY, USA

Trial

Phase 3, CheckMate649

Conference

ESMO 2021

Type

Peer-reviewed article

19 November 2021 09:41

ESMO 2021 Highlights Podcast

Presented By

Dr Rachel Giles, Medicom

Trial

DESTINY-Breast03, MONALEESA-2, KEYNOTE-716, CASPIAN, CheckMate-649, Impower010

Conference

ESMO 2021

4 October 2021 09:27

Benefit of I-O/chemo combo over chemotherapy alone in advanced GC/GEJC/EAC

Presented By

Prof. Markus Moehler, Mainz University Clinic, Germany

Trial

Phase 3, CheckMate 649

Conference

ASCO 2021

Type

Peer-reviewed article

12 August 2021 19:15

Nivolumab plus chemotherapy: new standard for first-line treatment of gastric cancer?

Conference

ESMO 2020

Type

Peer-reviewed article

25 November 2020 15:08